Zacks Research Has Bullish Outlook for PBH FY2025 Earnings

Prestige Consumer Healthcare Inc. (NYSE:PBH) – Research analysts at Zacks Research upped their FY2025 earnings per share (EPS) estimates for shares of Prestige Consumer Healthcare in a note issued to investors on Wednesday, February 26th. Zacks Research analyst R. Department now forecasts that the company will post earnings per share of $4.58 for the year, up from their prior forecast of $4.51. The consensus estimate for Prestige Consumer Healthcare’s current full-year earnings is $4.50 per share. Zacks Research also issued estimates for Prestige Consumer Healthcare’s Q4 2025 earnings at $1.29 EPS, Q1 2026 earnings at $0.99 EPS, Q2 2026 earnings at $1.17 EPS, Q4 2026 earnings at $1.36 EPS, FY2026 earnings at $4.76 EPS, Q1 2027 earnings at $1.09 EPS and FY2027 earnings at $5.03 EPS.

Prestige Consumer Healthcare (NYSE:PBH) last issued its quarterly earnings results on Thursday, February 6th. The company reported $1.22 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.18 by $0.04. Prestige Consumer Healthcare had a net margin of 19.13% and a return on equity of 12.36%.

PBH has been the subject of a number of other research reports. Canaccord Genuity Group lifted their price target on shares of Prestige Consumer Healthcare from $93.00 to $100.00 and gave the stock a “buy” rating in a research note on Friday, February 7th. Sidoti lowered shares of Prestige Consumer Healthcare from a “buy” rating to a “neutral” rating and set a $90.00 price target for the company. in a research note on Monday, December 9th. DA Davidson lifted their price target on shares of Prestige Consumer Healthcare from $95.00 to $104.00 and gave the stock a “buy” rating in a research note on Friday, February 7th. Oppenheimer lifted their price objective on shares of Prestige Consumer Healthcare from $87.00 to $93.00 and gave the stock an “outperform” rating in a report on Thursday, February 13th. Finally, StockNews.com raised shares of Prestige Consumer Healthcare from a “hold” rating to a “buy” rating in a report on Friday, January 24th. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $92.60.

Prestige Consumer Healthcare Stock Up 1.0 %

Shares of NYSE:PBH opened at $84.61 on Friday. The company has a current ratio of 3.68, a quick ratio of 2.20 and a debt-to-equity ratio of 0.56. The company has a fifty day simple moving average of $80.04 and a 200 day simple moving average of $77.14. The firm has a market cap of $4.19 billion, a PE ratio of 19.81, a price-to-earnings-growth ratio of 2.69 and a beta of 0.50. Prestige Consumer Healthcare has a 12-month low of $62.35 and a 12-month high of $88.36.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in PBH. Kayne Anderson Rudnick Investment Management LLC acquired a new position in Prestige Consumer Healthcare during the 4th quarter valued at about $84,932,000. Raymond James Financial Inc. bought a new stake in shares of Prestige Consumer Healthcare during the fourth quarter valued at approximately $42,593,000. Norges Bank acquired a new position in shares of Prestige Consumer Healthcare during the fourth quarter worth approximately $40,009,000. Bessemer Group Inc. grew its holdings in Prestige Consumer Healthcare by 10,053.1% in the 4th quarter. Bessemer Group Inc. now owns 295,050 shares of the company’s stock worth $23,041,000 after buying an additional 292,144 shares in the last quarter. Finally, Boston Trust Walden Corp increased its position in Prestige Consumer Healthcare by 43.5% in the 4th quarter. Boston Trust Walden Corp now owns 831,627 shares of the company’s stock valued at $64,942,000 after acquiring an additional 252,089 shares during the period. Institutional investors and hedge funds own 99.95% of the company’s stock.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.